BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 2532080)

  • 1. Effects of calcium entry blockade on hypertension-induced left ventricular hypertrophy.
    Frishman WH; Skolnick AE; Strom JA
    Circulation; 1989 Dec; 80(6 Suppl):IV151-61. PubMed ID: 2532080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antihypertensive therapy on hypertensive heart disease.
    Messerli FH; Kaesser UR; Losem CJ
    Circulation; 1989 Dec; 80(6 Suppl):IV145-50. PubMed ID: 2532079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
    Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
    Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic regression of cardiac hypertrophy in experimental hypertension.
    Pfeffer MA; Pfeffer JM
    J Cardiovasc Pharmacol; 1984; 6 Suppl 6():S865-9. PubMed ID: 6084141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of sympathetic nervous activity on regression of cardiac hypertrophy.
    Strauer BE; Bayer F; Brecht HM; Motz W
    J Hypertens Suppl; 1985 Dec; 3(4):S39-44. PubMed ID: 2937889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An evaluation of the therapeutic trials aimed at regression of ventricular hypertrophy in arterial hypertension].
    Clémenty J; Dulhoste MN; Bordier P; Lartigue MC; Pons N
    Ann Cardiol Angeiol (Paris); 1991 Oct; 40(8):503-8. PubMed ID: 1836942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ACE inhibition: mechanisms of cardioprotection in heart hypertrophy].
    Motz W; Strauer BE
    Klin Wochenschr; 1991; 69 Suppl 24():39-43; discussion 43-4. PubMed ID: 1830911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of renin-angiotensin system activity to left ventricular hypertrophy and function in experimental and human hypertension.
    Devereux RB; Pickering TG; Cody RJ; Laragh JH
    J Clin Hypertens; 1987 Mar; 3(1):87-103. PubMed ID: 3033158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular structural changes in hypertension: possible regression during long-term antihypertensive treatment.
    Novo S; Abrignani MG; Corda M; Strano A
    Eur Heart J; 1991 Dec; 12 Suppl G():47-52. PubMed ID: 1839619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antihypertensive therapy on left ventricular hypertrophy in essential hypertension.
    Frohlich ED
    Adv Nephrol Necker Hosp; 1990; 19():87-100. PubMed ID: 1967894
    [No Abstract]   [Full Text] [Related]  

  • 12. [A comparative study of cardiac function in transgenic hypertensive rats, in spontaneously hypertensive rats and in normotensive rats].
    Bohlender J; Hildenbrand U; Schlegel WP; Hempel P; Nissen E; Krause EG; Bartel S
    Arch Mal Coeur Vaiss; 2000 Aug; 93(8):993-6. PubMed ID: 10989744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of cardiac hypertrophy with drug treatment in spontaneously hypertensive rats.
    Ruskoaho H
    Med Biol; 1984; 62(5):263-76. PubMed ID: 6152298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I.
    Donohue TJ; Dworkin LD; Ma J; Lango MN; Catanese VM
    J Investig Med; 1997 Dec; 45(9):584-91. PubMed ID: 9444886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH; Alfayoumi F
    Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations in treating hypertension: focus on risk factors.
    Messerli FH
    J Hum Hypertens; 1990 Dec; 4 Suppl 5():3-6. PubMed ID: 2151045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Arterial hypertension, myocardial hypertrophy and disorders of cardiac rhythm induced by ligation of the left coronary artery in the rat].
    BĂ©lichard P; Pruneau D; Rochette L
    Arch Mal Coeur Vaiss; 1987 Jun; 80(6):883-7. PubMed ID: 2959234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Origin and evaluation of depressed inotropism in hypertensive cardiomyopathy.
    Viallard JF; Bonoron-Adele S; Dos Santos P; Coste P; Besse P
    Eur Heart J; 1993 Nov; 14 Suppl J():82-7. PubMed ID: 8281970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium-channel blockers for combined systemic hypertension and myocardial ischemia.
    Frishman WH; Charlap S
    Circulation; 1987 Jun; 75(6 Pt 2):V154-62. PubMed ID: 3552312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.